Mark S. Cragg

21.0k total citations · 1 hit paper
198 papers, 10.2k citations indexed

About

Mark S. Cragg is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Mark S. Cragg has authored 198 papers receiving a total of 10.2k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Radiology, Nuclear Medicine and Imaging, 95 papers in Immunology and 77 papers in Molecular Biology. Recurrent topics in Mark S. Cragg's work include Monoclonal and Polyclonal Antibodies Research (97 papers), Chronic Lymphocytic Leukemia Research (46 papers) and T-cell and B-cell Immunology (44 papers). Mark S. Cragg is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (97 papers), Chronic Lymphocytic Leukemia Research (46 papers) and T-cell and B-cell Immunology (44 papers). Mark S. Cragg collaborates with scholars based in United Kingdom, United States and Latvia. Mark S. Cragg's co-authors include Martin J. Glennie, Jekaterina Ērenpreisa, Ruth R. French, Stephen A. Beers, H.T. Claude Chan, Andreas Strasser, Peter Johnson, Tim Illidge, Claire A. Walshe and Ronald P. Taylor and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Mark S. Cragg

191 papers receiving 9.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain

2017 504 citations Mark S. Cragg, Diego Gómez‐Nicola et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Mark S. Cragg	4.0k	3.8k	3.3k	3.0k	1.8k	198	10.2k
Robert J. Kreitman	7.2k 1.8×	4.0k 1.1×	3.0k 0.9×	3.1k 1.1×	1.6k 0.9×	243	12.4k
Martin J. Glennie	5.6k 1.4×	2.5k 0.7×	4.1k 1.2×	3.2k 1.1×	1.9k 1.1×	148	9.7k
Yutaka Kawakami	9.0k 2.2×	6.0k 1.6×	1.3k 0.4×	5.5k 1.8×	915 0.5×	263	15.1k
André Veillette	9.9k 2.5×	5.7k 1.5×	1.8k 0.5×	3.5k 1.2×	441 0.2×	182	14.7k
Martin J.S. Dyer	4.9k 1.2×	6.3k 1.7×	1.5k 0.5×	4.6k 1.6×	6.5k 3.6×	300	16.5k
Gerhard Moldenhauer	2.9k 0.7×	3.4k 0.9×	1.8k 0.5×	2.7k 0.9×	548 0.3×	129	7.6k
John Laterra	690 0.2×	5.2k 1.4×	2.5k 0.8×	2.1k 0.7×	766 0.4×	214	11.3k
Amy B. Heimberger	8.2k 2.0×	5.3k 1.4×	969 0.3×	6.9k 2.3×	734 0.4×	272	17.5k
Albert J. Wong	1.3k 0.3×	6.3k 1.7×	1.2k 0.4×	3.8k 1.3×	611 0.3×	94	10.5k
Olli Silvennoinen	6.6k 1.6×	7.0k 1.9×	576 0.2×	8.5k 2.9×	1.3k 0.7×	159	16.7k

Countries citing papers authored by Mark S. Cragg

Since Specialization

Citations

This map shows the geographic impact of Mark S. Cragg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark S. Cragg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark S. Cragg more than expected).

Fields of papers citing papers by Mark S. Cragg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark S. Cragg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark S. Cragg. The network helps show where Mark S. Cragg may publish in the future.

Co-authorship network of co-authors of Mark S. Cragg

This figure shows the co-authorship network connecting the top 25 collaborators of Mark S. Cragg. A scholar is included among the top collaborators of Mark S. Cragg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark S. Cragg. Mark S. Cragg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leandro, Maria, Mark S. Cragg, Florian Kollert, et al.. (2024). P179 CD19hi B cells express T-bet and display activated metabolism and function in rheumatoid arthritis and systemic lupus erythematosus patient samples. Lara D. Veeken. 63(Supplement_1). 1 indexed citations

Rohrberg, Kristoffer Staal, Zsuzsanna Pápai, Rikke Løvendahl Eefsen, et al.. (2024). 19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.. Journal of Clinical Oncology. 42(16_suppl). 2641–2641. 1 indexed citations

Foxall, Russell B., Kerry L. Cox, Robert Oldham, et al.. (2024). CD40L and IL-4 suppress NK cell-mediated antibody-dependent cellular cytotoxicity through the HLA-E:NKG2A axis. PubMed. 5(1). ltaf029–ltaf029.

Johnson, Peter, Yosef Landesman, Mark S. Cragg, et al.. (2023). XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression. Leukemia. 37(10). 2036–2049. 12 indexed citations

Marshall, Michael J., Alexander Knaupp, Christian Spick, et al.. (2023). Development of C1q Affinity Chromatography for the Study of C1q–IgG Interactions. The Journal of Immunology. 210(11). 1837–1848. 2 indexed citations

Nimmerjahn, Falk, Gestur Vidarsson, & Mark S. Cragg. (2023). Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy. Nature Immunology. 24(8). 1244–1255. 55 indexed citations

Orr, Christian M., Xiaojie Yu, H.T. Claude Chan, et al.. (2022). Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Science Immunology. 7(73). eabm3723–eabm3723. 30 indexed citations

Kawai, Atsushi, et al.. (2021). Synergistic effect of non-neutralizing antibodies and interferon-γ for cross-protection against influenza. iScience. 24(10). 103131–103131. 11 indexed citations

Edelmann, Jennifer, Karlheinz Holzmann, D. Britton, et al.. (2021). Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. iScience. 24(2). 102089–102089. 16 indexed citations

10.

Ērenpreisa, Jekaterina, Kristīne Salmiņa, Olga V. Anatskaya, & Mark S. Cragg. (2020). Paradoxes of cancer: Survival at the brink. Seminars in Cancer Biology. 81. 119–131. 52 indexed citations

11.

Cox, Kerry L., Christine A. Penfold, Ruth R. French, et al.. (2018). Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific Reports. 8(1). 2278–2278. 30 indexed citations

12.

Dahal, Lekh N., Lang Dou, Khiyam Hussain, et al.. (2017). STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research. 77(13). 3619–3631. 59 indexed citations

13.

Li, Demin, Kirstie L.S. Cleary, Nicola Ternette, et al.. (2017). Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy. Cancer Research. 77(10). 2699–2711. 29 indexed citations

14.

Klymenko, Tetyana, Johannes Bloehdorn, Jasmin Bahlo, et al.. (2017). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia. 32(2). 364–375. 22 indexed citations

15.

Pauls, Samantha D., et al.. (2016). FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells. The Journal of Immunology. 197(5). 1587–1596. 11 indexed citations

16.

Hargreaves, Chantal E., Matthew Rose‐Zerilli, Lee R. Machado, et al.. (2015). Fcγ receptors: genetic variation, function, and disease. Immunological Reviews. 268(1). 6–24. 69 indexed citations

17.

Vaughan, Andrew, Mark S. Cragg, & Stephen A. Beers. (2015). Antibody modulation: Limiting the efficacy of therapeutic antibodies. Pharmacological Research. 99. 269–275. 9 indexed citations

18.

Williams, Emily L., Sonya James, Peter Johnson, et al.. (2013). Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model. Clinical Cancer Research. 19(13). 3545–3555. 34 indexed citations

19.

Alduaij, Waleed, Andrei Ivanov, Jamie Honeychurch, et al.. (2011). Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 117(17). 4519–4529. 222 indexed citations

20.

Beers, Stephen A., Ruth R. French, H.T. Claude Chan, et al.. (2010). Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood. 115(25). 5191–5201. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact